GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

6 Months Ended

Apr. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill balances and movements for each reportable segment during the period

The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2021:

	Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total
	(in millions)
Goodwill as of October 31, 2020	$	1,441	$	1,599	$	562	$	3,602
Foreign currency translation impact	9		3		5		17
Goodwill arising from acquisitions and adjustments	—		435		—		435
Goodwill as of April 30, 2021	$	1,450	$	2,037	$	567	$	4,054

Components of other intangible assets during the period

The component parts of other intangible assets as of April 30, 2021 and October 31, 2020 are shown in the table below:

 

	Other Intangible Assets
	Gross Carrying Amount		Accumulated Amortization		Net Book Value
	(in millions)
As of October 31, 2020
Purchased technology	$	1,429	$	863	$	566
Trademark/Tradename	196		117		79
Customer relationships	330		158		172
Third-party technology and licenses	11		7		4
Total amortizable intangible assets	1,966		1,145		821
In-Process R&D	10		—		10
Total	$	1,976	$	1,145	$	831
As of April 30, 2021
Purchased technology	$	1,661	$	916	$	745
Backlog	8		—		8
Trademark/Tradename	196		125		71
Customer relationships	360		193		167
Third-party technology and licenses	11		8		3
Total amortizable intangible assets	2,236		1,242		994
In-Process R&D	11		—		11
Total	$	2,247	$	1,242	$	1,005

Schedule of estimated future amortization expense of finite-lived intangible assets

Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2021 and for each of the next five fiscal years and thereafter is estimated below:

Estimated future amortization expense:
(in millions)
Remainder of 2021	$	99
2022	$	181
2023	$	133
2024	$	112
2025	$	86
2026	$	56
Thereafter	$	327